Status:
COMPLETED
Current Adoption of Composite Indices in Evaluating Rheumatoid Arthritis Patients: An Observational Study
Lead Sponsor:
Pfizer
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study of composite indices, including the CLARA (CLinical ARthritis Activity) index, in rheumatoid arthritis (RA) patients in routine clinical practice in Italy in order to ev...
Detailed Description
All patients who respond to inclusion/exclusion criteria at baseline will be considered valuable for the analysis.
Eligibility Criteria
Inclusion
- Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) criteria and in accordance with local guidelines.
- Patients eligible to anti-TNF therapy
- Patients naïve to anti-TNFa drugs
- Patients with radiography (hands and feet) executed by 6 months before the baseline or at baseline according to modified Sharp Van der Hejde method \[Sharp JT et al. 1985; Sharp JT. Et al. 1989; Van der Heijde DM et al. 1989\] Patients capable of understanding and completing the questionnaire Patients capable of understanding and signing an informed consent form
Exclusion
- Patients with tumors
- Patients already included in clinical trials
Key Trial Info
Start Date :
January 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
293 Patients enrolled
Trial Details
Trial ID
NCT00793403
Start Date
January 1 2008
End Date
June 1 2010
Last Update
February 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Torino, Italy, 10128